logo
Share SHARE
FONT-SIZE Plus   Neg

Select Medical Holdings Q1 Profit Rises; Backs FY12 Outlook - Quick Facts

Select Medical Holdings Corp. (SEM) reported first-quarter net income attributable to the company of $41.5 million or $0.29 per share, compared to $33.7 million or $0.22 per share last year.

On average, eight analysts polled by Thomson Reuters expected earnings of $0.25 per share for the quarter. Analysts' estimate typically excludes one-time items.

Net operating revenues for the quarter increased 7.3 percent to $744.02 million from $693.19 million in the same quarter last year, while seven analysts estimated revenues of $720.43 million for the quarter.

Looking forward, the company expects income per share for full year 2012 to be in the range of $0.86 to $0.94 and consolidated revenue in the range of $2.85 billion to $2.95 billion. Analysts currently expect earnings of $0.90 per share and revenue of $2.91 billion for the full year.

Further, the board of directors of Select Medical authorized an increase of $100.0 million in the capacity of its common stock repurchase program from $150.0 million to $250.0 million. The program will remain in effect until March 31, 2013, unless extended by the board of directors.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT